KNOWLEDGE BANK

Interviews

Interpharm Consultancy

Founder
Interpharm Consultancy has been providing advice about the UK generic market and consultancy services to generic manufacturers and distributors

Articles

The Role of Genomics in Shaping the Future of Medicine

Sequencing of the Human Genome at the beginning of the st century followed by the technological advances in Next Generation Sequencing NGS bioinformatics analysis tools and computational fire power have helped in making sequencingbased tests affordable and accessible for diagnostics and research purposes This has brought about a revolution in the field of modern medicine impacting greatly the drug...

Research Insights

CRISPR-Analytics (CRISPR-A): A Platform for Precise Analytics and Simulations for Gene Editing

CRISPRbased gene editing has become a fundamental toolbox to cover a large variety of research and applied needs

Case Studies

An Observational Case Study Of Prescription Patterns Of Antibiotics In Treating Lower Respiratory Tract Infections

Abstract Antibiotics are of the oldest discovered drugs that combat specific micro organisms like bacteria and fungi Although there are several classification schemes for antibiotics based on bacterial spectrum broad vs narrow or route of administration injectable vs oral vs topical or type of activity bactericidal vs bacteriostatic the most usefu

Techno Trends

Pfizer Launches First-of-its-kind ABRYSVO™ Vaccine for Prevention of Respiratory Syncytial Virus in Pregnant Individuals

Pfizer has introduced the first and only ABRYSVO vaccine designed to combat lower respiratory tract disease LRTD and severe LRTD caused by RSV in infants from birth to six months

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

The Regulatory Landscape for Nutraceuticals

Suresh Garg

Suresh Garg is the CMD and Founder of Zeon Life Sciences. He has over 30 years of extensive experience in the fields of nutrition, dairy products, healthcare, and nutraceuticals. Under his leadership, Zeon has become a pioneer in contract manufacturing for nutraceuticals and herbal goods. Owing to his passion and ability to thrive in a variety of sociocultural environments, Zeon has entered international markets.

 

2

Unleashing the Power of Data, Collaboration, and Innovation in Drug Development

Pooja Arora

Pooja is a Healthcare & Life Sciences leader at Thoughtworks with over 15 years of experience in technology consulting. Specialising in AI-driven solutions and strategic initiatives that enhance drug discovery and patient care, she has a unique background in both bioinformatics and product management. Passionate about navigating ambiguity and solving customer problems, Pooja’s current focus is on leveraging emerging technologies to accelerate innovation in healthcare and life sciences.

3

The Exosome Manufacturing Gap

Dr Deepika Arora

Dr Deepika Arora is an accomplished professional with expertise in project management, process improvement, and operational excellence. She brings strong scientific expertise and experience in prolific biologics, contributing to innovation and quality-driven outcomes. With a commitment to continuous learning, she has led cross-functional initiatives across diverse industries and writes on leadership, strategy, and professional development.

Aditya Banerjee

Aditya Banerjee is a senior scientist specialising in stem cell biology, regenerative medicine, and translational research. His work focuses on GMP-compliant cell therapy manufacturing, exosome research, and quality systems. Passionate about advancing scientific innovation, he writes on emerging biotechnologies, laboratory excellence, and their translation into meaningful clinical applications.

4

Magnetic Nanoparticles and their Application Studies on Synthesis Characterisation

Prabhanjan S Giram

Prabhanjan S Giram qualified CSIR-NET AIR-81 in chemical sciences and received his Ph. D from National chemical laboratory, Pune. He Received Eudragit® 2018 Award of 1500 Euros from Evonik health care Germany. He also received newton Bhabha Fellowship from British council, UK and DBT, India. He has expertise in synthesis of biocompatible, biodegradable polymer with rationalised design of nanoformulation, nanofiber, semisolid dosage form such as ointment, creams, and gel.

 

Shubham R Musale

Shubham R Musale has graduate in pharmacy from Savitribai Phule Pune University. He got fellowship for M.pharm from AICTE. The Thesis titled for M.pharm Design of In-expensive Collector for preparation Electrospun Nanofiber. He has 2 review publication and 1 Book Chapter.

 

Sushil Y Raut

Sushil Y Raut has over 12 years of teaching and research experience. He has more than 25 research and review publications. He filed 3 Indian patents and over 20 national as well as international presentations in his credits. He is recipient of international research mobility fellowship and other prestigious awards.

 

5

Covid -19 and Nanoparticles

Ramendra Pati Pandey

Ramendra Pati Pandey is an Assistant Professor in the Department of Biotechnology/Microbiology/Biomedical Engineering at the SRM University, Delhi-NCR, Sonepat. He was a FAPESP Post-Doctoral Fellow a very prestigious fellowship of Latin America at the Department of Medicine-InCor/HC-FMUSP, University of Sao Paulo, Brazil.

 

Deepika

Deepika has completed here master degree from Department of Biotechnology, Deenbandhu Choturam University and Technology, Sonepat, Haryana, India.

 

Reshma

Reshma completed her master's degree from the Royal Global University in Guwahati, Assam, India's department of Biotechnology.

 

Neehasri

Neehasri holds a master's degree in Zoology from Gauhati University in Guwahati, Assam, India, and has also passed the B.Ed. professional exam.

 

press releasesRead more...

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma

Shanghai Junshi Biosciences Co Ltd a leading innovationdriven biopharmaceutical company dedicated to the discovery development and commercialization of novel therapies announced that the supplemental new drug application for the companys product toripalimab injection subcutaneous injection

HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia

HUTCHMED China Limited today announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia ITP an autoimmune disorder that can lead to increased

Transpharmation Ltd. Announces Strategic Acquisition of OrganoTherapeutics SARL

Were delighted to announce the strategic acquisition of OrganoTherapeutics SARL a leader in patientderived organoid technologies that advance the discovery and development of novel therapies for neurodegenerativeCNS disorders

EVERSANA Expands Global Commercialization and AI-Powered HEOR Capabilities with Acquisition of U.K.-based Estima Scientific

EVERSANA a global provider of modern AIpowered commercial services for the biopharmaceutical industry today announced the acquisition of Estima Scientific an innovative Londonbased health economics and outcomes research HEOR technology and services company

Enhertu approved in the EU as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer

AstraZeneca and Daiichi Sankyos Enhertu trastuzumab deruxtecan has been approved in the European Union EU as a monotherapy for the adjuvant treatment of adult patients with resected HERpositive breast cancer who have residual invasive disease after neoadjuvant taxanebased and HERtargeted treatment

Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline

Teva Pharmaceuticals International GmbH a subsidiary of Teva Pharmaceutical Industries Ltd today announced that it has completed the acquisition of assets from BioXcel Therapeutics Inc including worldwide rights to BXCL BXCL is an investigational dexmedetomidine

EventsRead more...

28 - 30

Oct 2026

02 - 04

Nov 2026

Pharma Forum EMEA 2026

Dom Pedro Lisboa Hotel, Lisbon...

02 - 04

Nov 2026

Cancer R&D 2026

Houston, TX, USA

03 - 05

Nov 2026

10th Dermatology Drug Development

Boston, Massachusetts at The C...

03 - 04

Nov 2026

PDA Aseptic Processing of Biopharma Conference

Sheraton Grand Incheon Hotel,...

04 - 05

Nov 2026

Advanced Therapies USA

Hynes Convention Center, Bosto...

05 - 05

Nov 2026

PDA Contamination Control Strategy Workshop

Sheraton Grand Incheon Hotel,...

09 - 11

Nov 2026

11th Microbiome Movement USA Summit

The Colonnade Hotel, Boston, M...

LATEST NEWSRead more...

Adalvo Acquires Romiplostim Biosimilar from Enzene

Adalvo has acquired a romiplostim biosimilar programme from Enzene expanding its portfolio of biosimilars and strengthening its presence in complex biological medicines The programme references Nplate romiplostim a medicine used to treat immune thrombocytopenia ITP in adults and children with chroni...

Twist Bioscience Launches Express Screening Antibodies for Faster Characterisation

Twist Bioscience has expanded its antibody production and characterisation portfolio with the launch of Twist Express Screening Antibodies a service designed to help researchers evaluate large numbers of antibody candidates more quickly The service uses a highthroughput cellfree production process t...

Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044

Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...

Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia

Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement

Pfizer’s TALZENNA Plus XTANDI Approved for Earlier Treatment of Metastatic Prostate Cancer

Pfizer has received approval from the US Food and Drug Administration FDA to expand the use of TALZENNA talazoparib in combination with XTANDI enzalutamide for men with metastatic prostate cancer that is sensitive to hormone treatment and has specific homologous recombination repair HRR gene mutatio...

Okomera Signs Agreement with Servier for Cancer Research Technology

Okomera has signed a commercial agreement with Servier to support the development of new cancer treatments using its tumour miniaturisation technology More than of oncology drug candidates fail to reach the market making it important to identify promising treatments at an early stage Okomeras platf...